{"id":40302,"date":"2021-07-13T11:03:31","date_gmt":"2021-07-13T10:03:31","guid":{"rendered":"http:\/\/touchoncology.com\/?post_type=media_gallery&#038;p=40302"},"modified":"2021-07-13T11:03:31","modified_gmt":"2021-07-13T10:03:31","slug":"elena-garralda-asco-2021-favezelimab-in-metastatic-colorectal-cancer","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/colorectal-cancer\/conference-hub\/elena-garralda-asco-2021-favezelimab-in-metastatic-colorectal-cancer\/","title":{"rendered":"Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer"},"content":{"rendered":"<p>touchONCOLOGY joins <strong>Dr Elena Garralda<\/strong> (Vall d&#8217;Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer.<\/p>\n<p>The abstract \u2018A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02720068\" target=\"_blank\" rel=\"noopener\">NCT02720068<\/a>)\u2019 (<a href=\"https:\/\/meetinglibrary.asco.org\/record\/196498\/abstract\" target=\"_blank\" rel=\"noopener\">abstract number 3584<\/a>) was presented at the 2021 ASCO Annual Meeting.<\/p>\n<p><strong>Citation<\/strong>: <em>J Clin Oncol 39<\/em>, 2021 (suppl 15; abstr 3584)<br \/>\n<strong>DOI<\/strong>: <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.3584\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2021.39.15_suppl.3584<\/a><\/p>\n<p><strong>Questions<\/strong><br \/>\n1. What is favezelimab (MK4280) and its mechanism of action? (00:14-00:39)<\/p>\n<p>2. What was the rationale for using favezelimab in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer that had progressed on two or more prior therapies? (00:39-01:33)<\/p>\n<p>3. Could you give us an overview of the phase I study and its findings? (01:33-03:08)<\/p>\n<p>4. Which patients had the best response to this combination? (03:08-03:30)<\/p>\n<p>5. What will be the next steps in the clinical development of favezelimab in this treatment setting? (03:30-04:08)<\/p>\n<p>6. What do you think is the most important aspect to consider with regards to immunotherapy in this patient subset? (04:08-04:42)<\/p>\n<p><strong>Disclosures<\/strong>: Research: Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene. Consultant\/Advisor: Roche\/Genentech, F.Hoffmann\/La Roche, Ellipses Pharma, Neomed Therapeutics1 Inc, Boehringer Ingelheim, Janssen Global Services, SeaGen, TFS, Alkermes, Thermo Fisher, Bristol-Mayers Squibb, MabDiscovery, Anaveon. Travel Grants: Bristol-Mayers Squibb, Merck Sharp &amp; Dohme, Menarini, Glycotope. Speakers Bureau: Merck Sharp &amp; Dohme, Roche, Thermo Fisher, Lilly. Clinical Trials PI or Co-PI (Institution): Affimed Gmbh, Amgen SA, Anaveon AG, AstraZeneca AB, Biontech Gmbh, Catalym Gmbh, Cytomx, F.Hoffmann, La Roche Ltd, F-Star Beta Limited, Genentech Inc, Genmab B.V., Hutchison Medipharma Limited, Icon, Imcheck Therapeutics, Immunocore Ltd, Janssen-Cilag SA, Medimmune Llc, Merck Kgga, Novartis Farmac\u00e9utica, S.A, Peptomyc, Ribon Therapeutics, Roche Farma SA, Seattle Genetics Inc, Symphogen A\/S, Taiho Pharma Usa Inc.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.<\/p>\n<p><em>Filmed in coverage of the 2021 ASCO Annual Meeting.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>touchONCOLOGY joins Dr Elena Garralda (Vall d&#8217;Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract \u2018A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)\u2019 (abstract number 3584) was presented at the 2021 ASCO [&hellip;]<\/p>\n","protected":false},"featured_media":40303,"template":"","class_list":["post-40302","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-colorectal-cancer","video_categories-asco-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/40302"}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":1,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/40302\/revisions"}],"predecessor-version":[{"id":40304,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/40302\/revisions\/40304"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/40303"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=40302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}